AXD2 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
ZYNRELEF Adoption & IGNITESustained, program-driven adoption of ZYNRELEF (111% unit growth via IGNITE 1.0 and a 38% expansion of targeted accounts in IGNITE 2.0) indicates durable commercial penetration into surgical formularies. Expanding account coverage creates recurring, procedure-linked demand that scales with salesforce investment and supports repeatable revenue growth over quarters.
APONVIE Guideline & Reimbursement GainsAPONVIE’s inclusion in top PONV guidelines (A1), broad P&T adoption across ~1,903 accounts and a permanent product‑specific J‑code materially improve institutional access and billing clarity. These structural coverage and coding gains reduce adoption friction, bolster sustained procedure uptake, and make revenue realization more predictable across health systems.
CINVANTI Oncology Franchise StabilityCINVANTI’s steady Q1 sales ($20.5M) and a durable NK1 exit share (~25%), plus the REIGNITE program expected to add ~$10M, provide a meaningful, diversified cash generation stream. A stable oncology franchise reduces reliance on a single product category, helps fund operations, and supports margin resilience while acute‑care products scale.
Bears Say
High Leverage / Thin EquityA very thin equity cushion (~$9M) against approximately $142M of debt (debt-to-equity ≈15.5x) materially constrains financial flexibility. Elevated leverage increases refinancing risk and the likelihood of dilutive equity raises or expensive financings to fund operations or growth, limiting the company’s ability to absorb shocks or invest opportunistically over the medium term.
Negative Operating & Free Cash FlowPersistent negative operating and free cash flow (~-$20M TTM) mean the business is not yet self‑funding and remains dependent on external capital. Continued cash burn elevates financing risk, increases probability of equity dilution or higher‑cost debt, and can force tradeoffs between commercial investment and near‑term liquidity management over multiple quarters.
Patent Invalidation Risk For CINVANTIA Delaware court ruling invalidating asserted CINVANTI patents introduces meaningful structural risk of generic entry that could erode a key cash‑generating franchise. Even with an appeal, loss of exclusivity or weaker IP protection would pressure CINVANTI revenues and margins, worsening funding needs and amplifying balance‑sheet and dilution concerns if realized.
Heron Therapeutics News
AXD2 FAQ
What was Heron Therapeutics Inc’s price range in the past 12 months?
Currently, no data Available
What is Heron Therapeutics Inc’s market cap?
Currently, no data Available
When is Heron Therapeutics Inc’s upcoming earnings report date?
Heron Therapeutics Inc’s upcoming earnings report date is Aug 11, 2026 which is in 17 days.
How were Heron Therapeutics Inc’s earnings last quarter?
Heron Therapeutics Inc released its earnings results on May 11, 2026. The company reported -$0.033 earnings per share for the quarter, missing the consensus estimate of -$0.019 by -$0.014.
Is Heron Therapeutics Inc overvalued?
According to Wall Street analysts Heron Therapeutics Inc’s price is currently Undervalued.
Does Heron Therapeutics Inc pay dividends?
Heron Therapeutics Inc does not currently pay dividends.
What is Heron Therapeutics Inc’s EPS estimate?
Heron Therapeutics Inc’s EPS estimate is >-0.01.
How many shares outstanding does Heron Therapeutics Inc have?
Currently, no data Available
What happened to Heron Therapeutics Inc’s price movement after its last earnings report?
Heron Therapeutics Inc reported an EPS of -$0.033 in its last earnings report, missing expectations of -$0.019. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Heron Therapeutics Inc?
Currently, no hedge funds are holding shares in CH:AXD2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Heron Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.58%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.44%
Trailing 12-Months
Company Description
Heron Therapeutics Inc
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
AXD2 Stock 12 Month Forecast
Average Price Target
$1.63
Ocugen
―
Benitec Biopharma
―
Kodiak Sciences
―
Sagimet Biosciences, Inc. Class A
―
Neumora Therapeutics, Inc.
―